within Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA01_Beclometasone;

model Beclometasone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.1666666666666665e-05,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.02,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.08,
    k12 = 0.000125,
    k21 = 0.000125);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Beclometasone</td></tr><tr><td>ATC code:</td><td>R03BA01</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>20</td><td>L</td></tr>
    <tr><td>clearance:</td><td>150</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Beclometasone is a synthetic corticosteroid with potent anti-inflammatory properties, commonly used as an inhaled treatment for asthma and allergic rhinitis. It acts by reducing airway inflammation and bronchial hyperresponsiveness. Beclometasone is approved and widely used in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data reported for healthy adult volunteers (both sexes) after inhalation administration.</p><h4>References</h4><ol><li><p>Kuna, P, et al., &amp; Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. <i>Pharmacology research &amp; perspectives</i> 10(4) e980–None. DOI:<a href=\"https://doi.org/10.1002/prp2.980\">10.1002/prp2.980</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35733414/\">https://pubmed.ncbi.nlm.nih.gov/35733414</a></p></li><li><p>Luo, Z, et al., &amp; Mariotti, F (2022). Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers. <i>Pulmonary pharmacology &amp; therapeutics</i> 73-74 102129–None. DOI:<a href=\"https://doi.org/10.1016/j.pupt.2022.102129\">10.1016/j.pupt.2022.102129</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35525480/\">https://pubmed.ncbi.nlm.nih.gov/35525480</a></p></li><li><p>Chawes, BL, et al., &amp; Bisgaard, H (2014). Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent. <i>Respiratory medicine</i> 108(8) 1108–1116. DOI:<a href=\"https://doi.org/10.1016/j.rmed.2014.05.007\">10.1016/j.rmed.2014.05.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24993817/\">https://pubmed.ncbi.nlm.nih.gov/24993817</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03BA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Beclometasone;
